Antiphospholipid syndrome and kidney disease
详细信息 查看全文
- 作者：Frank Bienaimé ; 1 ; 2 ; 3 ; Christophe Legendre1 ; 3 ; 4 ; Fabiola Terzi1 ; 3 ; Guillaume Canaud1 ; 3 ; 4 ; guillaume.canaud@inserm.fr
- 关键词：antiphospholipid antibodies ; mTORC pathway ; vasculopathy
- 刊名：Kidney International
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：91
- 期：1
- 页码：34-44
- 全文大小：2396 K
- 卷排序：91
文摘
The antiphospholipid syndrome is a common autoimmune disease caused by pathogenic antiphospholipid antibodies, leading to recurrent thrombosis and/or obstetrical complications. Importantly for nephrologists, antiphospholipid antibodies are associated with various renal manifestations including large renal vessel thrombosis, renal artery stenosis, and a constellation of intrarenal lesions that has been termed antiphospholipid nephropathy. This last condition associates various degrees of acute thrombotic microangiopathy, proliferative and fibrotic lesions of the intrarenal vessels, and ischemic modifications of the renal parenchyma. The course of the disease can range from indolent nephropathy to devastating acute renal failure. The pejorative impact of antiphospholipid antibody–related renal complication is well established in the context of systemic lupus erythematous or after renal transplantation. In contrast, the exact significance of isolated antiphospholipid nephropathy remains uncertain. The evidence to guide management of the renal complications of antiphospholipid syndrome is limited. However, the recent recognition of the heterogeneous molecular mechanisms underlying the progression of intrarenal vascular lesions in antiphospholipid syndrome have opened promising tracks for patient monitoring and targeted therapeutic intervention.